Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation
Current Oncology · 2025
DOI: 10.3390/curroncol32060294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Wei-Jie Ran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Core Binding Factor Alpha 2 Subunit, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Major Program of the National Natural Science Foundation of China.
Abstract (Originalsprache)
It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognostic impact of RUNX1 mutations following allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing clinical outcomes in AML patients with and without RUNX1 mutations. We retrospectively analyzed 91 AML patients (33 RUNX1+ and 58 RUNX1−) who received their first HSCT at Peking University People’s Hospital. The median age of the cohort was 38 years (range: 6–64), with 73 patients (80%) receiving Haploidentical HSCT and 18 patients (20%) receiving sibling-matched allo-HSCT. In univariate analyses, no significant differences in survival outcomes were observed. For the RUNX1-mutation group and RUNX1-wild-type group, the 2-year cumulative incidence of relapse (CIR) was (12.6% vs. 7.6%, p = 0.472), the 2-year non-relapse mortality (NRM) rate was (9.6% vs. 7.2%, p = 0.747), the 2-year LFS was (77.8% vs. 85.2%, p = 0.426), and the 2-year OS rate was (85.9% vs. 92.7%, p = 0.397). We did not observe any negative impact of RUNX1 mutations on clinical outcomes, suggesting that allo-HSCT (especially Haplo-HSCT) may mitigate the adverse prognostic influence of RUNX1 mutations in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative…
ORCID-Profile: Ying-Jun Chang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Major Program of the National Natural Science Foundation of China
- Beijing Research Ward Excellence Program
- Beijing Municipal Science & Technology Commission
- Peking University Medicine Fund for world’s leading discipline or discipline cluster development
Zitieren
APA
Ran, W. J., Xu, L. P., Zhang, X. H., Chang, Y. J., Mo, X. D., Sun, Y. Q., Huang, X. J., & Wang, Y. (2025). Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation. Current Oncology. https://doi.org/10.3390/curroncol32060294
Vancouver
Ran WJ, Xu LP, Zhang XH, Chang YJ, Mo XD, Sun YQ, et al. Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation. Current Oncology. 2025. doi:10.3390/curroncol32060294
BibTeX
@article{Ran2025,
author = {Ran, Wei-Jie and Xu, Lan-Ping and Zhang, Xiao-Hui and Chang, Ying-Jun and Mo, Xiao-Dong and Sun, Yu-Qian and Huang, Xiao-Jun and Wang, Yu},
title = {Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32060294}
}
EUVIMED